Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-07-18

Clinical Trial Update: A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study results for dacomitinib in advanced non-small cell lung cancer have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dacomitinib (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-07-18